Quoin Pharmaceuticals, Ltd.
QNRX
$19.00
-$0.17-0.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.40M | 6.11M | 5.92M | 5.91M | 5.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.18M | 12.68M | 11.03M | 9.53M | 9.34M |
| Operating Income | -14.18M | -12.68M | -11.03M | -9.53M | -9.34M |
| Income Before Tax | -13.77M | -12.17M | -10.45M | -8.96M | -8.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.77 | -12.17 | -10.45 | -8.96 | -8.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.77M | -12.17M | -10.45M | -8.96M | -8.70M |
| EBIT | -14.18M | -12.68M | -11.03M | -9.53M | -9.34M |
| EBITDA | -14.08M | -12.58M | -10.93M | -9.43M | -9.24M |
| EPS Basic | -1.12K | -1.45K | -1.71K | -2.84K | -4.95K |
| Normalized Basic EPS | -19.92 | -25.90 | -30.52 | -50.66 | -88.35 |
| EPS Diluted | -1.12K | -1.46K | -1.72K | -2.84K | -4.95K |
| Normalized Diluted EPS | -19.92 | -25.90 | -30.52 | -50.66 | -88.35 |
| Average Basic Shares Outstanding | 1.95M | 1.51M | 1.06M | 535.60K | 376.90K |
| Average Diluted Shares Outstanding | 55.60K | 42.90K | 30.20K | 15.20K | 10.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |